We report the case of a patient followed for a mixed connective tissue disease with signs of systemic sclerosis and systemic lupus, who presented an acute renal failure with severe neurological symptoms (confusion, obnubilation) and hypertension. The distinction between scleroderma renal crisis and lupus nephritis was challenging and hence, the decision to use or not high dose of corticosteroids. Kidney biopsy was of major importance for the diagnosis and therapeutic strategy. The diagnosis of neurological symptoms was also made difficult given the clinical presentation and the results of imaging. Neurolupus, malignant hypertension, or posterior reversible encephalopathy syndrome were the evoked diagnosis.
FanouriakisAKostopoulouMCheemaK, et al. 2019 update of the joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis2020; 79(6): 713–723.
2.
Kowal-BieleckaOFransenJAvouacJ, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis2017; 76(8): 1327–1339.
3.
YamashitaHKameiRKanekoH.Classifications of scleroderma renal crisis and reconsideration of its pathophysiology. Rheumatology2019; 58: 2099–2106.
4.
ZanattaECodulloVAllanoreY, et al. Scleroderma renal crisis: case reports and update on critical issues. Eur J Rheumatol2020; 8: 162–167.
5.
TaylanATekinEEnginB.Glomerulonephritis and Coombs-positive hemolytic anemia mimicking scleroderma renal crisis in an overlap of systemic lupus erythematosus and diffuse systemic sclerosis. Rheumatol Int2020; 40(5): 785–789.
SharpGCIrvinWSTanEM, et al. Mixed connective tissue disease—an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med1972; 52(2): 148–159.
8.
MadiehJKhamaysehIHrizatA, et al. Scleroderma renal crisis in a case of mixed connective tissue disease treated successfully with angiotensin-converting enzyme inhibitors. Case Rep Nephrol2021; 2021: 8862405.
DingYTanYQuZ, et al. Renal microvascular lesions in lupus nephritis. Ren Fail2020; 42(1): 19–29.
11.
FugateJERabinsteinAA.Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol2015; 14(9): 914–925.
12.
KobatakeMIshimaruNKanzawaY, et al. Recurring posterior reversible encephalopathy syndrome in a patient with polymyositis/systemic sclerosis overlap syndrome triggered by scleroderma renal crisis. Eur J Rheumatol2019; 6(3): 158–160.
13.
YongPFHamourSMBurnsA.Reversible posterior leukoencephalopathy in a patient with systemic sclerosis/systemic lupus erythematosus overlap syndrome. Nephrol Dial Transplant2003; 18(12): 2660–2662.
14.
GomezJJhonstonEJZevallosF.Posterior reversible encephalopathy syndrome in a patient with systemic lupus erythematosus/systemic sclerosis overlap syndrome. Case Rep Rheumatol2014; 2014: 862570.
15.
Valdez-LópezMAguirre-AguilarEValdés-FerrerSI, et al. Posterior reversible encephalopathy syndrome: a neuropsychiatric manifestation of systemic lupus erythematosus. Autoimmun Rev2021; 20: 102739.
16.
PennHHowieAJKingdonEJ, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM2007; 100(8): 485–494.
17.
ZanattaEPolitoPFavaroM, et al. Therapy of scleroderma renal crisis: state of the art. Autoimmun Rev2018; 17(9): 882–889.
